Swiss National Bank Has $10.34 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)

Swiss National Bank lifted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 219,800 shares of the biopharmaceutical company’s stock after buying an additional 4,300 shares during the period. Swiss National Bank owned about 0.19% of Cytokinetics worth $10,339,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of CYTK. Jones Financial Companies Lllp increased its holdings in shares of Cytokinetics by 189.8% during the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 374 shares in the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Cytokinetics during the fourth quarter worth $29,000. AlphaQuest LLC grew its stake in shares of Cytokinetics by 113,500.0% in the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,135 shares during the last quarter. J.Safra Asset Management Corp grew its stake in shares of Cytokinetics by 62.1% in the fourth quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 671 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Cytokinetics by 85.8% in the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 842 shares during the last quarter.

Insider Activity at Cytokinetics

In other Cytokinetics news, CEO Robert I. Blum sold 16,970 shares of Cytokinetics stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $43.44, for a total transaction of $737,176.80. Following the transaction, the chief executive officer now owns 364,181 shares of the company’s stock, valued at $15,820,022.64. This trade represents a 4.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $49.32, for a total transaction of $98,640.00. Following the transaction, the executive vice president now directly owns 116,071 shares in the company, valued at approximately $5,724,621.72. This represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 43,834 shares of company stock valued at $1,949,275. 3.40% of the stock is owned by corporate insiders.

Cytokinetics Price Performance

Shares of NASDAQ CYTK opened at $43.10 on Friday. Cytokinetics, Incorporated has a fifty-two week low of $40.53 and a fifty-two week high of $75.71. The stock has a market cap of $5.10 billion, a price-to-earnings ratio of -8.01 and a beta of 0.95. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The firm’s 50-day simple moving average is $45.99 and its 200 day simple moving average is $50.04.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to the consensus estimate of $14.26 million. As a group, research analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Mizuho boosted their price objective on shares of Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. HC Wainwright reissued a “buy” rating and issued a $120.00 price objective on shares of Cytokinetics in a research note on Friday, February 28th. Evercore ISI raised shares of Cytokinetics to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley set a $67.00 price objective on shares of Cytokinetics in a research note on Friday, March 7th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $78.00 price target on shares of Cytokinetics in a research report on Friday, February 7th. Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $82.00.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.